(5R)-3-{3-fluoro-4-[6-((5S)-5-{[(2-methoxyethoxy)methoxy]methyl}-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]phenyl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5R)-3-{3-fluoro-4-[6-((5S)-5-{[(2-methoxyethoxy)methoxy]methyl}-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]phenyl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one
• 英文别名: (5R)-3-[3-fluoro-4-[(5S)-5-[{[(2-methoxyethoxy)methoxy]methyl}-4,5-dihydroisoxazol-3-yl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one；(5R)-3-[3-fluoro-4-[6-[(5S)-5-(2-methoxyethoxymethoxymethyl)-4,5-dihydro-1,2-oxazol-3-yl]pyridin-3-yl]phenyl]-5-(triazol-1-ylmethyl)-1,3-oxazolidin-2-one
• 化学式: C₂₅H₂₇FN₆O₆
• 分子量: 526.524
• InChiKey: ZZTIRQDXNGUUMX-PMACEKPBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  38
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  122
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  (5R)-3-[3-fluoro-4-[((5S)-5-hydroxymethyl-4,5-dihydroisoxazol-3-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-one 、 2-甲氧基乙氧基甲基氯 在 N,N-二异丙基乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 以87%的产率得到(5R)-3-{3-fluoro-4-[6-((5S)-5-{[(2-methoxyethoxy)methoxy]methyl}-4,5-dihydroisoxazol-3-yl)pyridin-3-yl]phenyl}-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one
  参考文献：
  名称：

  [EN] HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS
  [FR] DERIVES DE DIHYDROISOXAZOLE A SUBSTITUTION HYDROXYMETHYLE POUVANT SERVIR D'AGENTS ANTIBIOTIQUES

  摘要：

  公式（I）的化合物，或其药学上可接受的盐，或其体内可水解的酯，（I）中R1a是NH(C=W)R5或（a）；W是O或S；R2和R3例如是H或F；R1例如是氢或卤素；R5从氢，（2-6C）烷基（可选地取代）中选择；R6和R7独立地从氢和（1-4C）烷基（可选地取代）中选择；其中R4是异噁唑环的C-4'上的羟甲基取代基；或R4是异噁唑环的C-5'上的羟甲基取代基，且异噁唑环的C-5'和噁唑烷酮环的C-5的立体化学被选择，使得公式（I）的化合物是单一对映体；它们作为抗菌剂是有用的；并描述了它们的制备方法和含有它们的药物组合物。

  公开号：

  WO2004078753A1

文献信息

• [EN] HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS<br/>[FR] DERIVES DE DIHYDROISOXAZOLE A SUBSTITUTION HYDROXYMETHYLE POUVANT SERVIR D'AGENTS ANTIBIOTIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004078753A1

  公开（公告）日：2004-09-16

  Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, (I) R1a is NH(C=W)R5 or (a); W is O or S; R2 and R3 are for example H or F; R1 is for example hydrogen, or halogen; R5 is selected from hydrogen, (2-6C)alkyl (optionally substituted); R6 and R7 are independently selected from hydrogen, and (1-4C)alkyl (optionally substituted); wherein R4 is either a hydroxymethyl substituent on C-4' of the isoxazoline ring; or R4 is a hydroxymethyl substituent on C-5' of the isoxazoline ring and the stereochemistry at C-5' of the isoxazoline ring and at C-5 of the oxazolidinone ring is selected, such that the compound of formula (I) is a single diastereomer; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  公式（I）的化合物，或其药学上可接受的盐，或其体内可水解的酯，（I）中R1a是NH(C=W)R5或（a）；W是O或S；R2和R3例如是H或F；R1例如是氢或卤素；R5从氢，（2-6C）烷基（可选地取代）中选择；R6和R7独立地从氢和（1-4C）烷基（可选地取代）中选择；其中R4是异噁唑环的C-4'上的羟甲基取代基；或R4是异噁唑环的C-5'上的羟甲基取代基，且异噁唑环的C-5'和噁唑烷酮环的C-5的立体化学被选择，使得公式（I）的化合物是单一对映体；它们作为抗菌剂是有用的；并描述了它们的制备方法和含有它们的药物组合物。
• Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents
  申请人：Gravestock Barry Michael

  公开号：US20060270637A1

  公开（公告）日：2006-11-30

  Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, (I) R1a is NH(C═W)R 5 or (a); W is O or S; R 2 and R 3 are for example H or F; R 1 is for example hydrogen, or halogen; R 5 is selected from hydrogen, (2-6C)alkyl (optionally substituted); R 6 and R 7 are independently selected from hydrogen, and (1-4C)alkyl (optionally substituted); wherein R 4 is either a hydroxymethyl substituent on C-4′ of the isoxazoline ring; or R 4 is a hydroxymethyl substituent on C-5′ of the isoxazoline ring and the stereochemistry at C-5′ of the isoxazoline ring and at C-5 of the oxazolidinone ring is selected, such that the compound of formula (I) is a single diastereomer; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  化合物的公式为(I)，或其药学上可接受的盐，或其体内可水解的酯，其中(I) R1a为NH(C═W)R5或(a)；W为O或S；R2和R3例如为H或F；R1例如为氢或卤素；R5选择自氢、(2-6C)烷基(可选取取代基)；R6和R7独立选择自氢和(1-4C)烷基(可选取取代基)；其中R4为在异氧杂环环的C-4'上的羟甲基取代基；或R4为在异氧杂环环的C-5'上的羟甲基取代基，并且异氧杂环环的C-5'和噁唑烷环的C-5的立体化学被选择，使得公式(I)的化合物是单一对映体。这些化合物作为抗菌剂有用，并且描述了制造它们的过程以及含有它们的制药组合物。
• HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS
  申请人：AstraZeneca AB

  公开号：EP1599471B1

  公开（公告）日：2008-05-28
• US7192974B2
  申请人：——

  公开号：US7192974B2

  公开（公告）日：2007-03-20
• [EN] OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES D'OXAZOLIDINONE ET/OU D'ISOXAZOLINE UTILISES COMME AGENTS ANTIBACTERIENS
  申请人：ASTRAZENECA AB

  公开号：WO2004048392A1

  公开（公告）日：2004-06-10

  A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: formula (I) wherein in (I) C is for example formula (D), formula (E), formula (H) wherein A and B are independently selected from (i) formula (J) and (ii) formula (K) m is 1 or 2; R2b and R6b, R2a and R6a, R3a and R5a, are for example selected from H, F, OMe and Me; R2b' and R6b', R2a' and R6a', R3a', R5a' are for example selected from H, OMe and Me; R1a is for example optionally substituted (1-10C)alkyl; R1b is for example selected from -NR5C(=W)R4, formula (a) , or formula (b) wherein HET-1 is for example isoxazolyl and HET-2 is for example triazolyl or tetrazolyl. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.

  公式（I）的化合物，或其药用可接受盐，或体内可水解酯：公式（I）其中在（I）中，C例如为公式（D），公式（E），公式（H）其中A和B分别选自（i）公式（J）和（ii）公式（K）m为1或2；R2b和R6b，R2a和R6a，R3a和R5a，例如选自H，F，OMe和Me；R2b'和R6b'，R2a'和R6a'，R3a'，R5a'例如选自H，OMe和Me；R1a例如为可选择地取代的（1-10C）烷基；R1b例如选自-NR5C(=W)R4，公式（a），或公式（b）其中HET-1例如为异恶唑基，HET-2例如为三唑基或四唑基。还描述了制备公式（I）的化合物的方法，含有它们的组合物以及它们作为抗菌剂的用途。